Why GLP-1 causes muscle loss
GLP-1 works by suppressing appetite. The drug does not know the difference between fat tissue and lean tissue. When you eat significantly less — which is the mechanism — your body draws energy from both fat stores and muscle protein. Without a deliberate signal to preserve muscle (resistance training + adequate protein), lean mass atrophies alongside fat.
The STEP-1 trial (semaglutide) showed that patients lost an average of 14.9% of body weight. Of that loss, approximately 39% was lean mass in patients without a structured exercise protocol. In the SURMOUNT-1 trial (tirzepatide), the figure was approximately 25–30% lean mass loss.
For a 200lb patient losing 30lbs, this means 7–12lbs of that loss is muscle — not fat. Muscle loss reduces metabolic rate, worsens body composition, increases fall risk, and makes long-term weight maintenance significantly harder.
The prevention protocol
01Protein: 1.6–2.2g/kg body weight daily
This is the most important single intervention. For a 180lb (82kg) patient, this means 131–180g of protein per day. GLP-1 dramatically suppresses appetite, which means most patients naturally eat far less protein than they need. A structured protein supplement is not optional on GLP-1 — it is clinical management of a known side effect. The WellSpry GLP-1 Protein Complex (25g per serving) is introduced at the protocol call as non-negotiable.
02Resistance training 3–4x per week
Compound movements — squats, Romanian deadlifts, bench press, rows — provide the mechanical stimulus that signals muscle retention to the body. Resistance training in the context of caloric restriction maintains muscle protein synthesis even when overall intake is reduced. Volume should be modestly reduced in weeks 1–4 when GI side effects are most common, then progressively increased.
03Track body composition — not just weight
A scale cannot tell you whether you are losing fat or muscle. DEXA scan or bioelectrical impedance should be used at baseline and every 90 days. This is why WellSpry includes quarterly re-testing — the biomarker data shows what is actually changing in body composition, allowing the physician to adjust the protocol in real time.
04Testosterone management in at-risk patients
Low testosterone is the strongest predictor of lean mass loss during GLP-1 therapy. Men with testosterone below 400 ng/dL and women below the low-normal range should have this addressed before or concurrently with GLP-1 initiation. CareValidate can prescribe TRT where clinically indicated. This is determined at the physician interpretation call from the baseline panel.
05CJC-1295/Ipamorelin at month 3 for high-risk patients
For patients who are showing lean mass loss at the 90-day body composition review despite adequate protein and resistance training, CJC-1295/Ipamorelin stimulates pulsatile growth hormone release — improving lean mass preservation, sleep quality, and metabolic rate. Introduced at the 90-day physician check-in when the data justifies it. Never sold directly. Always physician-prescribed via 503A pharmacy.
WellSpry tests testosterone, cortisol, and body composition markers before any protocol is designed. Your physician builds your prevention strategy from real data — not population averages.
Get My Testing Kit — $399 →Frequently Asked Questions
Does GLP-1 cause muscle loss?
Yes. GLP-1 receptor agonists including semaglutide and tirzepatide suppress appetite without distinguishing between fat and lean mass. Clinical trials show average lean mass loss of 25–39% of total weight lost without a structured resistance training and protein protocol.
How much protein should I eat on semaglutide?
Clinical evidence supports 1.6–2.2g of protein per kilogram of body weight per day to preserve lean mass during GLP-1 therapy. For a 180lb (82kg) patient, this means 131–180g of protein daily. Most patients on GLP-1 eat significantly less protein than this due to appetite suppression — which is why targeted protein supplementation is essential.
What exercises prevent muscle loss on Wegovy?
Resistance training 3–4 times per week with compound movements (squats, deadlifts, presses, rows) is the most effective intervention for preserving lean mass during GLP-1 therapy. Volume should be reduced in the first 4 weeks (when GI side effects peak) and progressively increased thereafter. Zone 2 cardio can be added but should not replace resistance training.
Does tirzepatide cause less muscle loss than semaglutide?
SURMOUNT-4 data suggests tirzepatide may preserve slightly more lean mass than semaglutide, likely due to its GIP mechanism which has anabolic signalling properties. However, the difference is modest — both require the same protein and resistance training protocol to meaningfully prevent lean mass loss.